158 related articles for article (PubMed ID: 23158991)
21. Clinical value of immunohistochemically detected lymphatic and vascular invasions in clinically staged endometrioid endometrial cancer.
Alexander-Sefre F; Nibbs R; Rafferty T; Ayhan A; Singh N; Jacobs I
Int J Gynecol Cancer; 2009 Aug; 19(6):1074-9. PubMed ID: 19820371
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of BAF57 expression in patients with endometrial carcinoma.
Kagami S; Kurita T; Kawagoe T; Toki N; Matsuura Y; Hachisuga T; Matsuyama A; Hashimoto H; Izumi H; Kohno K
Histol Histopathol; 2012 May; 27(5):593-9. PubMed ID: 22419023
[TBL] [Abstract][Full Text] [Related]
23. High Twist expression is involved in infiltrative endometrial cancer and affects patient survival.
Kyo S; Sakaguchi J; Ohno S; Mizumoto Y; Maida Y; Hashimoto M; Nakamura M; Takakura M; Nakajima M; Masutomi K; Inoue M
Hum Pathol; 2006 Apr; 37(4):431-8. PubMed ID: 16564917
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of hysteroscopic imaging in endometrioid endometrial adenocarcinoma.
Garuti G; De Giorgi O; Sambruni I; Cellani F; Luerti M
Gynecol Oncol; 2001 Jun; 81(3):408-13. PubMed ID: 11371130
[TBL] [Abstract][Full Text] [Related]
25. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
26. [Significance of prognostic evaluation of International Federation of Gynecology and Obstetrics 2009 staging system on stage I endometrioid adenocarcinoma].
Wang ZQ; Zhang Y; Wang JL; Shen DH; Mu T; Zhao X; Yao YY; Bai Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):33-9. PubMed ID: 22455691
[TBL] [Abstract][Full Text] [Related]
27. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
28. [Expression and clinical significance of Beclin1 and PTEN in endometrial carcinoma].
Zhao JH; Wan XY; Xie X; Zhou CY; Wu QY
Ai Zheng; 2006 Jun; 25(6):753-7. PubMed ID: 16764775
[TBL] [Abstract][Full Text] [Related]
29. Metabolic syndrome is an independent prognostic factor for endometrial adenocarcinoma.
Ni J; Zhu T; Zhao L; Che F; Chen Y; Shou H; Yu A
Clin Transl Oncol; 2015 Oct; 17(10):835-9. PubMed ID: 26260911
[TBL] [Abstract][Full Text] [Related]
30. [Possibility of PTEN expression on predicting pathologic risk factors of endometrioid adenocarcinoma before operation].
Lou HY; Lin kQ; Ye DF; Xie X; Yu X
Ai Zheng; 2005 Jun; 24(6):748-50. PubMed ID: 15946494
[TBL] [Abstract][Full Text] [Related]
31. [Expression and relationship of Ezh2, Runx3 and caspase-3 in endometrial adenocarcinoma].
Guo ZL; Chen K; Wang XQ; Hu W
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):387-91. PubMed ID: 21914347
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression.
Bing L; Hong C; Li-Xin S; Wei G
Arch Gynecol Obstet; 2014 Sep; 290(3):533-41. PubMed ID: 24699721
[TBL] [Abstract][Full Text] [Related]
33. Association between Morphological Patterns of Myometrial Invasion and Cancer Stem Cell Markers in Endometrial Endometrioid Carcinoma.
Park JY; Hong D; Park JY
Pathol Oncol Res; 2019 Jan; 25(1):123-130. PubMed ID: 28990139
[TBL] [Abstract][Full Text] [Related]
34. Immunoexpression of the PTEN protein and matrix metalloproteinase-2 in endometrial cysts, endometrioid and clear cell ovarian cancer.
Brucka A; Szyłło K
Ginekol Pol; 2013 May; 84(5):344-51. PubMed ID: 23819399
[TBL] [Abstract][Full Text] [Related]
35. Reproducibility of grading systems for endometrial endometrioid carcinoma and their relation with pathologic prognostic parameters.
Kapucuoglu N; Bulbul D; Tulunay G; Temel MA
Int J Gynecol Cancer; 2008; 18(4):790-6. PubMed ID: 17892460
[TBL] [Abstract][Full Text] [Related]
36. Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma.
Karahan N; Güney M; Baspinar S; Oral B; Kapucuoglu N; Mungan T
Eur J Gynaecol Oncol; 2007; 28(3):184-8. PubMed ID: 17624083
[TBL] [Abstract][Full Text] [Related]
37. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.
Obata T; Nakamura M; Mizumoto Y; Iizuka T; Ono M; Terakawa J; Daikoku T; Fujiwara H
PLoS One; 2017; 12(11):e0188641. PubMed ID: 29190668
[TBL] [Abstract][Full Text] [Related]
38. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
40. Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma.
Montserrat N; Mozos A; Llobet D; Dolcet X; Pons C; de Herreros AG; Matias-Guiu X; Prat J
Hum Pathol; 2012 May; 43(5):632-43. PubMed ID: 21940036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
